证券代码：688139 证券简称：海尔生物 公告编号：2024-035 青岛海尔生物医疗股份有限公司 关于举办 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 青岛海尔生物医疗股份有限公司（以下简称"公司"）为便于广大投资者进一 步全面深入地了解公司 2023 年度经营成果、财务状况、发展理念，公司定于 2024 年 05 月 15 日(星期三)15:00-16:30 在全景网举办 2023 年度业绩说明会，本次说 明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次业绩说明会。 出席本次业绩说明会的人员有：总经理刘占杰先生、首席财务官莫瑞娟女士、 董事会秘书黄艳莉女士。 为充分尊重投资者，提升交流的针对性，现就公司 2023 年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2024 年 05 月 14 日(星期二)16:30 前访问 http://ir.p5w.net/zj/，或扫描下方二维 ...

证券代码：688139 证券简称：海尔生物 公告编号：2024-034 青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 截至 2024 年 4 月 30 日，青岛海尔生物医疗股份有限公司（以下简称 "公司"）通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股 份 815,617 股，占公司总股本 317,952,508 股的比例为 0.26%，回购成交的最 高价为 32.31 元/股，最低价为 27.40 元/股,支付的资金总额为人民币 25,654,978.48 元（不含交易费用）。 一、回购股份的基本情况 公司于 2024 年 2 月 8 日召开第二届董事会第十七次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方 案"），同意公司以自有资金通过上海证券交易所交易系统以集中竞价交易方式 回购公司已发行的部分人民币普通股（A 股）股票。回购的股份将在未来适宜 时机全部用于员工持股计划 ...

证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2024-009 投资者关系活动 R特定对象调研 □分析师会议 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他 （请文字说明其他活动内容） 参与单位名称 博时基金、东吴证券、广发基金、国泰基金、华夏基金、建 信养老、诺安基金、泰康基金、新华基金、中信建投、中邮 证券11家机构。 ...

Investment Rating - The report maintains a "Recommended" rating for Haier Biomedical (688139) [1] Core Views - Domestic business shows steady growth with Q1 2024 revenue reaching 499 million yuan, a year-on-year increase of 11% and a quarter-on-quarter increase of 80% [1] - Overseas business faces temporary pressure, with Q1 2024 revenue of 186 million yuan, showing a year-on-year decline but a quarter-on-quarter growth of 6% [1] - The Life Sciences segment benefits from laboratory construction opportunities, achieving Q1 2024 revenue of 350 million yuan, a quarter-on-quarter increase of 79% [1] - The Medical Innovation segment sees Q1 2024 revenue of 334 million yuan, a quarter-on-quarter increase of 31%, driven by new infrastructure and public health recovery [1] - Continuous R&D investment supports accelerated development of new industries, with Q1 2024 R&D expenses at 77 million yuan, accounting for 11.25% of total revenue [1] - The company expects net profit for 2024-2026 to be 500 million, 610 million, and 750 million yuan respectively, with corresponding PE ratios of 24, 19, and 16 times [1] Financial Summary - Total revenue for 2023 was 2,281 million yuan, with a year-on-year decline of 20.4% [3] - Projected total revenue for 2024 is 2,776 million yuan, with a year-on-year growth of 21.7% [3] - Net profit for 2023 was 406 million yuan, with a year-on-year decline of 32.4% [3] - Projected net profit for 2024 is 496 million yuan, with a year-on-year growth of 22.2% [3] - The company’s total market value is approximately 11.748 billion yuan [4]

证券研究报告·公司点评报告·医疗器械 2024 年一季报点评：Q1 业绩超预期，Q2 拐 点将至 2024 年 04 月 29 日 | --- | --- | --- | --- | --- | --- | |------------------------------|---------|---------|--------|--------|--------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 2,864 | 2,281 | 2,863 | 3,436 | 4,054 | | 同比（ % ） | 34.72 | (20.36) | 25.54 | 20.00 | 17.99 | | 归母净利润（百万元） | 600.79 | 406.07 | 573.42 | 703.76 | 850.56 | | 同比（ % ） | (28.90) | (32.41) | 41.21 | 22.73 | 20.86 | | EPS- 最新摊薄（元 / 股） | 1.89 | 1.28 | 1.80 ...

证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2024-008 投资者关系活动 R特定对象调研 □分析师会议 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他 （请文字说明其他活动内容） 参与单位名称 共95家机构，参会机构名单详见附表。 时间 2024年4月26日 参会方式 电话会议 上市公司接待人 总经理刘占杰及莫瑞娟、王稳夫、王广生、陈海涛、巩燚、 ...

www.chinastock.com.cn 证券研究报告 请务必阅读正文最后的中国银河证券股份有限公司免责声明 （一）公司财务预测表 [Table_ReportTypeIndex] 公司点评 [Table_AuthorsRxplain] 本人承诺以勤勉的执业态度，独立、客观地出具本报告，本报告清晰准确地反映本人的研究观点。本人薪酬的任何部分过去不 曾与、现在不与、未来也将不会与本报告的具体推荐或观点直接或间接相关。 [Table_Avow] 本报告由中国银河证券股份有限公司（以下简称银河证券）向其客户提供。银河证券无需因接收人收到本报告而视其为客户。 若您并非银河证券客户中的专业投资者，为保证服务质量、控制投资风险、应首先联系银河证券机构销售部门或客户经理，完成投 资者适当性匹配，并充分了解该项服务的性质、特点、使用的注意事项以及若不当使用可能带来的风险或损失。 本报告所载的全部内容只提供给客户做参考之用，并不构成对客户的投资咨询建议，并非作为买卖、认购证券或其它金融工具 的邀请或保证。客户不应单纯依靠本报告而取代自我独立判断。银河证券认为本报告资料来源是可靠的，所载内容及观点客观公正， 但不担保其准确性或完 ...

2024 年 4 月 25 日 公司基本情况 总股本/流通股本（亿股）3.18 / 3.18 资产负债率(%) 19.6% 第一大股东青岛海尔生物医疗控股 有限公司 股票投资评级 个股表现 研究所 海尔生物(688139) 事件：公司发布 2024 年一季报：2024Q1 营业收入 6.87 亿元，实 现在去年同期高基数压力下同比增幅 0.04%，环比增幅 51%，相比去 年二三季度分别增幅 18%和 24%的高增长。第一季度公司归母净利润 1.38 亿元，同比增长 0.06%，环比增长 182%；扣非归母净利润 1.33 亿元，同比增长 7%，环比增长 251%。归母净利润率和扣非归母净利 润率分别为 20%和 19%，环比分别提升 9%和 11%，随着收入提升和持 续的降本增效，期间费率大幅改善，盈利能力回归常态。 围绕生命科学和医疗创新场景，2024Q1 在非存储产品系列化布局 继续完善，新产业占收入比重达 39%，同比增长 22%，环比增长 36%， 多品类发展新格局进一步夯实。其中，在生命科学领域推出光照/霉 菌培养箱、落地式高速冷冻离心机、全自动细胞培养工作站等新产品 方案；在医疗创新领域推出普药 ...

Investment Rating - The investment rating for the company is "Buy - A" with a 6-month target price of 43.27 CNY [7][22]. Core Views - The company has captured structural opportunities in the industry and continues to see rapid growth in new business segments [2][6]. - The domestic market achieved revenue of 4.99 billion CNY in Q1 2024, representing a year-on-year growth of 11% and a quarter-on-quarter growth of 80% [20]. - The overseas market generated revenue of 1.86 billion CNY, showing a quarter-on-quarter growth of 6%, although there was a year-on-year decline due to project execution cycles [20]. Financial Performance - In Q1 2024, the company reported revenue of 6.87 billion CNY, a year-on-year increase of 0.04% and a quarter-on-quarter increase of 51% [5][6]. - The net profit attributable to shareholders was 1.38 billion CNY, with a year-on-year growth of 0.06% and a quarter-on-quarter growth of 182% [5]. - The gross profit margin stood at 49.6%, with net profit margin and non-recurring net profit margin at 20% and 19% respectively, both showing significant quarter-on-quarter improvements [5]. Business Segments - The life sciences segment generated revenue of 3.5 billion CNY in Q1 2024, with a quarter-on-quarter growth of 79% [6]. - The medical innovation segment achieved revenue of 3.34 billion CNY, reflecting a quarter-on-quarter growth of 31% [6]. - New industries accounted for 39% of total revenue, with a year-on-year growth of 22% and a quarter-on-quarter growth of 36% [6]. Market Outlook - The company is expected to maintain strong revenue growth rates of 26.4%, 25.0%, and 23.5% for the years 2024 to 2026 respectively [22]. - Net profit growth rates are projected at 35.5%, 25.3%, and 25.1% for the same period, indicating robust growth potential [22].

Financial Performance - In Q1 2024, the company's domestic market revenue reached RMB 499 million, representing a year-on-year growth of 11% and a quarter-on-quarter growth of 80%[9] - The overseas market generated revenue of RMB 186 million, showing a 6% quarter-on-quarter increase despite a year-on-year decline due to project execution cycles[9] - Total operating revenue for Q1 2024 was ¥686,909,061.52, slightly up from ¥686,668,622.18 in Q1 2023, representing a growth of 0.035%[20] - The company's operating revenue for Q1 2024 was CNY 686,909,061.52, reflecting a year-on-year increase of 0.04%[44] - Net profit attributable to shareholders of the listed company reached CNY 137,614,697.49, up 0.06% year-on-year[44] - In Q1 2024, the company achieved a net profit attributable to shareholders of 138 million RMB, a year-on-year increase of 0.06% and a quarter-on-quarter increase of 182%[64] - The company's net profit from investments was ¥3,291,655.49 in Q1 2024, a decrease from ¥13,015,767.85 in Q1 2023, representing a decline of about 74.7%[20] Cash Flow and Assets - The net cash flow from operating activities was RMB 77.2 million, a decrease of 27.34% compared to the previous period[5] - The net cash flow from investment activities for Q1 2024 was -¥7,529,404.95, compared to ¥243,627,690.30 in Q1 2023, showing a significant decline[25] - Cash and cash equivalents at the end of Q1 2024 amounted to ¥1,307,071,714.34, an increase from ¥1,260,604,285.14 at the end of Q4 2023[25] - The total assets at the end of the reporting period amounted to RMB 5.69 billion, reflecting a 2.92% increase from the end of the previous year[5] - The total assets increased to ¥2,457,000,000.00 as of March 31, 2024, compared to ¥2,400,000,000.00 at the end of 2023, indicating a growth of approximately 2.4%[30] Liabilities and Equity - The total liabilities as of March 31, 2024, were ¥1,130,338,492.54, up from ¥1,085,719,569.95 at the end of 2023, reflecting an increase of approximately 4.1%[32] - The total equity attributable to shareholders of the parent company increased to CNY 4,342,842,117.06 from CNY 4,230,710,929.50, marking a growth of approximately 2.64%[33] - The total liabilities and equity amounted to CNY 5,686,835,629.15, up from CNY 5,525,682,568.67, reflecting an increase of about 2.91%[33] Research and Development - The company's R&D investment totaled RMB 77.3 million, accounting for 11.25% of operating revenue, which is a decrease of 0.4 percentage points[5] - Research and development expenses were ¥77,257,984.27 in Q1 2024, down from ¥80,011,141.60 in Q1 2023, indicating a decrease of about 3.4%[20] - The company plans to focus on technological innovation to support the accelerated development of new industries[6] - The company is focusing on expanding its automation applications in life sciences and medical innovation, enhancing its product offerings in these sectors[61] Product Development and Market Strategy - The company launched several new products in Q1 2024, including a light/mold incubator and a fully automated cell culture workstation, enhancing its product offerings in the life sciences sector[45] - The company is focusing on strengthening its direct user engagement capabilities in both domestic and international markets[46] - The company benefited from VAT refunds amounting to approximately 3.86 million RMB, related to software products developed in-house[66] - The company also received government subsidies related to assets amounting to 729,177.13 RMB, which are expected to have a lasting impact on its financial performance[66] Profitability and Cost Management - The gross profit margin for the first quarter improved significantly, with the net profit margin reaching 20% and the non-recurring net profit margin at 19%, both showing substantial quarter-on-quarter increases[64] - The company has seen a significant improvement in cost management, contributing to enhanced profitability and operational efficiency[64] Shareholder Information - Major shareholder China Bank holds 5,212,089 shares, representing 1.64% of total shares[70] - The top 10 shareholders collectively hold 416,500 shares, accounting for 0.13%[70] - The total number of shares lent out in the stock borrowing program at the end of the period is 222,400, which is 0.07% of total shares[70] - The total number of unrestricted circulating shares participating in the stock borrowing program is 5,406,189, representing 1.7%[70]